Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587777660> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W2587777660 endingPage "vii16" @default.
- W2587777660 startingPage "vii15" @default.
- W2587777660 abstract "According to the World Health Organization grading system for neuroendocrine neoplasms, neuroendocrine carcinoma (NEC) is a poorly differentiated, high-grade malignant tumor, including small and large cell carcinoma. The primary sites of NEC vary, with gastroenteropancreatic NEC (GEP-NEC) accounting for 20%–68% of extra-pulmonary NEC. Treatment guidelines for advanced extra-pulmonary NEC recommend platinum-based chemotherapy regimens, which are suitable for small cell lung carcinoma. There are two large-scale, multicenter retrospective analyses of advanced GEP-NEC: the NORDIC NEC study [Sorbye H et al. Ann Oncol. 2013;24(1)] and the Japanese study [Yamaguchi et al. Cancer Sci. 2014;105(9)]. In both studies, GEP-NEC prognoses varied according to primary organs. Although only etoposide plus cisplatin regimen (EP) was the mainstream first line chemotherapy in NORDIC, EP and irinotecan plus cisplatin regimen (IP) were commonly used in Japan. Both regimens (EP, IP) have been demonstrated to show favorable efficacy and have been acknowledged as de facto standard regimens for advanced NEC, although it remains unclear which of the two regimens might yield more favorable outcomes. Therefore, a phase III study comparing EP and IP in terms of overall survival for patients with recurrent or unresectable GEP-NEC (TOPIC-NEC, UMIN000014795) has been commenced by the Japan Clinical Oncology Group (JCOG). The sample size was set as 140 (70 patients per arm). For second line regimens, amrubicin, irinotecan, and S-1 were commonly utilized in Japan, but no standard regimens have been established. A multicenter phase II study to evaluate the efficacy of everolimus in pancreatic NEC patients who are unresponsive to/intolerant of platinum-based regimens (NECTOR: UMIN000012752) is currently in progress." @default.
- W2587777660 created "2017-02-24" @default.
- W2587777660 creator A5005262911 @default.
- W2587777660 date "2016-11-01" @default.
- W2587777660 modified "2023-09-30" @default.
- W2587777660 title "Current status and perspective of systemic chemotherapies for GEP-NEC" @default.
- W2587777660 doi "https://doi.org/10.1093/annonc/mdw463.004" @default.
- W2587777660 hasPublicationYear "2016" @default.
- W2587777660 type Work @default.
- W2587777660 sameAs 2587777660 @default.
- W2587777660 citedByCount "0" @default.
- W2587777660 crossrefType "journal-article" @default.
- W2587777660 hasAuthorship W2587777660A5005262911 @default.
- W2587777660 hasBestOaLocation W25877776601 @default.
- W2587777660 hasConcept C121608353 @default.
- W2587777660 hasConcept C126322002 @default.
- W2587777660 hasConcept C143998085 @default.
- W2587777660 hasConcept C2776694085 @default.
- W2587777660 hasConcept C2776907518 @default.
- W2587777660 hasConcept C2778119113 @default.
- W2587777660 hasConcept C2778336483 @default.
- W2587777660 hasConcept C2779292878 @default.
- W2587777660 hasConcept C2780259306 @default.
- W2587777660 hasConcept C2781413609 @default.
- W2587777660 hasConcept C526805850 @default.
- W2587777660 hasConcept C71924100 @default.
- W2587777660 hasConceptScore W2587777660C121608353 @default.
- W2587777660 hasConceptScore W2587777660C126322002 @default.
- W2587777660 hasConceptScore W2587777660C143998085 @default.
- W2587777660 hasConceptScore W2587777660C2776694085 @default.
- W2587777660 hasConceptScore W2587777660C2776907518 @default.
- W2587777660 hasConceptScore W2587777660C2778119113 @default.
- W2587777660 hasConceptScore W2587777660C2778336483 @default.
- W2587777660 hasConceptScore W2587777660C2779292878 @default.
- W2587777660 hasConceptScore W2587777660C2780259306 @default.
- W2587777660 hasConceptScore W2587777660C2781413609 @default.
- W2587777660 hasConceptScore W2587777660C526805850 @default.
- W2587777660 hasConceptScore W2587777660C71924100 @default.
- W2587777660 hasLocation W25877776601 @default.
- W2587777660 hasOpenAccess W2587777660 @default.
- W2587777660 hasPrimaryLocation W25877776601 @default.
- W2587777660 hasRelatedWork W1568769885 @default.
- W2587777660 hasRelatedWork W1904016001 @default.
- W2587777660 hasRelatedWork W2077980843 @default.
- W2587777660 hasRelatedWork W2084101102 @default.
- W2587777660 hasRelatedWork W2086955530 @default.
- W2587777660 hasRelatedWork W2221781456 @default.
- W2587777660 hasRelatedWork W2559759225 @default.
- W2587777660 hasRelatedWork W2745803145 @default.
- W2587777660 hasRelatedWork W2889443765 @default.
- W2587777660 hasRelatedWork W3215662100 @default.
- W2587777660 hasVolume "27" @default.
- W2587777660 isParatext "false" @default.
- W2587777660 isRetracted "false" @default.
- W2587777660 magId "2587777660" @default.
- W2587777660 workType "article" @default.